Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Perspective Therapeutics (CATX) over the last 10 years, with Q3 2025 value amounting to $65000.0.

  • Perspective Therapeutics' Interest Expenses fell 579.71% to $65000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $239000.0, marking a year-over-year increase of 6482.76%. This contributed to the annual value of $48000.0 for FY2024, which is 4146.34% down from last year.
  • As of Q3 2025, Perspective Therapeutics' Interest Expenses stood at $65000.0, which was down 579.71% from $119000.0 recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' Interest Expenses registered a high of $128000.0 during Q1 2025, and its lowest value of -$73000.0 during Q4 2024.
  • In the last 3 years, Perspective Therapeutics' Interest Expenses had a median value of $26000.0 in 2023 and averaged $40181.8.
  • In the last 5 years, Perspective Therapeutics' Interest Expenses plummeted by 40416.67% in 2024 and then surged by 41739.13% in 2025.
  • Perspective Therapeutics' Interest Expenses (Quarter) stood at $24000.0 in 2023, then plummeted by 404.17% to -$73000.0 in 2024, then soared by 189.04% to $65000.0 in 2025.
  • Its Interest Expenses stands at $65000.0 for Q3 2025, versus $119000.0 for Q2 2025 and $128000.0 for Q1 2025.